Sugi Predict

Sugi Predict / Compounds / SCHEMBL400044

SCHEMBL400044

SCHEMBL400044

CC(=O)c1ccc(Cl)cc1N

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 1/20 0.65
▸ FLT1 P17948 1/20 0.50
▸ FLT4 P35916 1/20 0.50
▸ KDR P35968 1/20 0.50
▸ SMN1; SMN2 Q16637 3/20 0.48
▸ ALDH1A1 P00352 3/20 0.48
▸ ALOX15 P16050 2/20 0.48
▸ CYP3A4 P08684 2/20 0.48
▸ HPGD P15428 1/20 0.48
▸ ALOX12 P18054 1/20 0.48
▸ MAPK1 P28482 1/20 0.48
▸ HSD17B10 Q99714 1/20 0.48
▸ TSHR P16473 3/20 0.48
▸ TDP1 Q9NUW8 1/20 0.48
▸ TP53 P04637 1/20 0.46
▸ CASP1 P29466 1/20 0.45
▸ MAPT P10636 2/20 0.45
▸ CA12 O43570 1/20 0.45
▸ CA9 Q16790 1/20 0.45
▸ MAOB P27338 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29758053 1.00 ABL1 (0.65) ABL1FLT1FLT4KDRSMN1; SMN2
Hydrochloric Acid SCHEMBL7423119 0.98 ABL1 (0.62) ABL1FLT1FLT4KDRSMN1; SMN2
SCHEMBL1189140 0.83 RECQL (0.58) ABL1SMN1; SMN2ALDH1A1ALOX15CYP3A4
Ethane SCHEMBL11678007 0.82 ABL1 (0.62) ABL1FLT1FLT4KDRSMN1; SMN2
SCHEMBL160570 0.81 ABL1 (0.61) ABL1FLT1FLT4KDRSMN1; SMN2
SCHEMBL128885 0.81 SMN1; SMN2 (0.63) ABL1FLT1FLT4KDRSMN1; SMN2
SCHEMBL20117002 0.80 ALDH1A1 (0.50) ABL1SMN1; SMN2ALDH1A1MAPK1HSD17B10
Hydrochloric Acid SCHEMBL6750016 0.79 SMN1; SMN2 (0.61) ABL1FLT1FLT4KDRSMN1; SMN2
SCHEMBL15602132 0.79 ABL1 (0.55) ABL1FLT1FLT4KDRSMN1; SMN2
SCHEMBL28303002 0.79 SMN1; SMN2 (0.61) ABL1FLT1FLT4KDRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4653053-A1 PPARG INVERSE AGONISTS AND USES THEREOF Flare Therapeutics, Inc. (US) 2025-11-26 — — EP disclosed
EP-4426434-B1 PPARG INVERSE AGONISTS AND USES THEREOF FLARE THERAPEUTICS INC (US) 2025-08-20 — — EP disclosed
US-20250145601-A1 NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS SATYA THERAPEUTICS, INC. 2025-05-08 — — US disclosed
US-12234244-B2 Substituted piperazines as inhibitors of KRAS G12C ARAXES PHARMA LLC (US) 2025-02-25 — — US disclosed
US-20240352028-A1 SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2024-10-24 — — US disclosed
US-20240166624-A1 PPARG INVERSE AGONISTS AND USES THEREOF FLARE THERAPEUTICS INC. 2024-05-23 — — US disclosed
CN-117616012-A PPARG inverse agonists and uses thereof 弗拉雷治疗公司 2024-02-27 — — CN disclosed
US-20240043441-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2024-02-08 — — US disclosed
US-11878985-B2 Substituted quinazolines as inhibitors of KRAS G12C ARAXES PHARMA LLC (US) 2024-01-23 — — US disclosed
US-11873291-B2 Quinoline cGAS antagonist compounds IMMUNESENSOR THERAPEUTICS, INC. (US) 2024-01-16 — — US disclosed
US-20060235031-A1 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-10-19 — — US disclosed
WO-2005097800-A1 6,6-BICYCLIC RING SUBSTITUTED HETEROBICYCLIC PROTEIN KINASE INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2005-10-20 — — WO disclosed
EP-0760819-B1 TRICYCLIC DICARBONYL DERIVATIVES HOFFMANN LA ROCHE (CH) 2000-07-19 — — EP disclosed
CN-1044245-C Tricyclic Dicarbonyl derivatives HAFFMANN LA ROCHE AG F (DE) 1999-07-21 — — CN disclosed
US-5688803-A BRAIN DISORDERS; PSYCHOLOGICAL DISORDERS HOFFMANN-LA ROCHE INC. (US) 1997-11-18 — — US disclosed
CN-1149295-A Tricyclic Dicarbonyl derivatives HOFFMANN LA ROCHE (CH) 1997-05-07 — — CN disclosed
EP-0760819-A1 TRICYCLIC DICARBONYL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 1997-03-12 — — EP disclosed
WO-1995032205-A1 TRICYCLIC DICARBONYL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 1995-11-30 — — WO disclosed
US-4379929-A BACTERIOSTATS ELI LILLY AND COMPANY (US) 1983-04-12 — — US disclosed
US-3987047-A ANORETICS BOEHRINGER INGELHEIM GMBH (DT) 1976-10-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240166624-A1 PPARG INVERSE AGONISTS AND USES THEREOF PPARG, PPARA, PPARD ABL1 3094/4885FLT1 1568/4885FLT4 1798/4885
US-12234244-B2 Substituted piperazines as inhibitors of KRAS G12C KRAS, NRAS, HRAS ABL1 67/4885FLT1 3249/4885FLT4 4150/4885
US-11873291-B2 Quinoline cGAS antagonist compounds CGAS, GLS2, GLS ABL1 407/4885FLT1 2799/4885FLT4 2208/4885
US-11878985-B2 Substituted quinazolines as inhibitors of KRAS G12C KRAS, NRAS, HRAS ABL1 82/4885FLT1 2468/4885FLT4 3722/4885
US-20240352028-A1 SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS ABL1 82/4885FLT1 2468/4885FLT4 3722/4885
US-20250145601-A1 NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS RAD51, ERCC4, ERCC2 ABL1 2954/4885FLT1 3451/4885FLT4 3967/4885
US-20240043441-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS ABL1 216/4885FLT1 2685/4885FLT4 4324/4885
US-20060235031-A1 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors IGF1R, MAP2K7, BRCA1 ABL1 621/4885FLT1 1319/4885FLT4 1133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.